Xenothera SAS   Report issue

For profit Phase 2 Phase 3
Founded: Nantes France (2014)

Organization Overview

First Clinical Trial
2019
NCT04431219
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Xenothera SAS